Assembly Biosciences, Inc. (NASDAQ:ASMB) Receives Average Rating of “Moderate Buy” from Analysts

Assembly Biosciences, Inc. (NASDAQ:ASMB) has been given a consensus recommendation of “Moderate Buy” by the eight ratings firms that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $41.00.

A number of brokerages have recently commented on ASMB. Mizuho set a $40.00 price objective on shares of Assembly Biosciences and gave the stock an “outperform” rating in a research note on Thursday, November 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Assembly Biosciences in a report on Wednesday, January 21st. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $50.00 price objective on shares of Assembly Biosciences in a report on Monday, December 22nd.

Assembly Biosciences Stock Performance

NASDAQ ASMB opened at $27.34 on Tuesday. The firm has a market capitalization of $432.52 million, a P/E ratio of -5.71 and a beta of 1.14. The stock has a 50-day simple moving average of $33.41 and a two-hundred day simple moving average of $28.01. Assembly Biosciences has a fifty-two week low of $7.75 and a fifty-two week high of $39.71.

Assembly Biosciences (NASDAQ:ASMB) last posted its earnings results on Monday, November 10th. The biopharmaceutical company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.50) by ($0.22). Assembly Biosciences had a negative return on equity of 59.01% and a negative net margin of 103.65%.The company had revenue of $10.79 million for the quarter, compared to analyst estimates of $7.46 million. As a group, analysts forecast that Assembly Biosciences will post -6.87 earnings per share for the current year.

Hedge Funds Weigh In On Assembly Biosciences

A number of large investors have recently bought and sold shares of ASMB. Palumbo Wealth Management LLC grew its holdings in Assembly Biosciences by 7.2% in the fourth quarter. Palumbo Wealth Management LLC now owns 37,305 shares of the biopharmaceutical company’s stock valued at $1,269,000 after purchasing an additional 2,507 shares during the period. Qube Research & Technologies Ltd purchased a new position in shares of Assembly Biosciences during the 3rd quarter valued at approximately $282,000. RA Capital Management L.P. acquired a new stake in Assembly Biosciences in the 3rd quarter valued at $26,122,000. Parkman Healthcare Partners LLC purchased a new stake in Assembly Biosciences in the 3rd quarter worth $6,425,000. Finally, Millennium Management LLC purchased a new stake in Assembly Biosciences in the 3rd quarter worth $553,000. Institutional investors and hedge funds own 19.92% of the company’s stock.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.